Xenetic Biosciences(XBIO)

4.285 0.00 0.0%

今开:0.0昨收:4.285
最高:0.0 最低:0.0
涨停价:0.0跌停价:0.0
总市值:6601831.0

Xenetic Biosciences的热门讨论

季度财报

Xenetic Biosciences(XBIO)05-10 05:05

$Xenetic Biosciences(XBIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001683168-24-003172  Act: 34  Size: 2 MB 网页链接查看全文

当期报告

Xenetic Biosciences(XBIO)06-22 04:35

$Xenetic Biosciences(XBIO)$ 8-K Current report, item 5.02 Accession Number: 0001683168-24-004415  Act: 34  Size: 245 KB 网页链接查看全文

当期报告

Xenetic Biosciences(XBIO)05-10 20:35

$Xenetic Biosciences(XBIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001683168-24-003192  Act: 34  Size: 284 KB 网页链接查看全文

持股变动声明

Xenetic Biosciences(XBIO)06-22 05:05

$Xenetic Biosciences(XBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001683168-24-004421  Size: 5 KB 网页链接查看全文

当期报告

Xenetic Biosciences(XBIO)05-23 05:05

$Xenetic Biosciences(XBIO)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0001683168-24-003779  Act: 34  Size: 274 KB 网页链接查看全文

其他

Xenetic Biosciences(XBIO)07-19 04:15

$Xenetic Biosciences(XBIO)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-24-000494  Act: 34  Size: 3 KB 网页链接查看全文

Xenetic Biosciences的最新讨论

药药药萌2023-04-24 19:00

$Xenetic Biosciences(XBIO)$ $石药集团(01093)$ $恒瑞医药(SH600276)$
PolyXen 平台 :PolyXen是蛋白质和肽药物输送的使能平台技术。它使用生物聚合物聚唾液酸(PSA)来延长药物的半衰期,并可能提高治疗肽和蛋白质的稳定性。附着部位和PSA链的长度都可以通过改变分子的表观流体力学半径来影...查看全文

Bio News |Xenetic 宣布与CLS Therapeutics合作

牛股小红书2022-04-28 13:48

$Xenetic Biosciences(XBIO)$ 与CLS Therapeutics签署了独家许可和再许可协议,以开发其基于DNA酶的介入性肿瘤学平台,旨在改善现有治疗,包括免疫疗法。
根据协议,Xenetic拥有CLS知识产权的独家许可证,用于在癌症中使用DNA酶,包括DNA酶与标准疗法(包括化疗、放疗和检查点抑制剂)的系统联...查看全文

Spica2021-09-02 07:32

$Xenetic Biosciences(XBIO)$ ?8月12日做了增发,3.65?网页链接查看全文

冷枪手假亦真2021-08-12 04:08

$Xenetic Biosciences(XBIO)$ 终于盈利了💵💵[大笑][大笑]查看全文

1 2 3 4 5 6 7 8

Xenetic Biosciences的公告

$Xenetic Biosciences(XBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001683168-19-003913  Size: 5 KB 网页链接

$Xenetic Biosciences(XBIO)$ 8-K Current report, item 5.07 Accession Number: 0001683168-19-003909  Act: 34  Size: 31 KB 网页链接

$Xenetic Biosciences(XBIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001683168-19-003668  Act: 34  Size: 288 KB 网页链接

$Xenetic Biosciences(XBIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001683168-19-003653  Act: 34  Size: 2 MB 网页链接

$Xenetic Biosciences(XBIO)$ DEF 14A - Other definitive proxy statements Filed: 2019-11-08 AccNo: 0001683168-19-003504 Size: 639 KB 网页链接

$Xenetic Biosciences(XBIO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-10-23 AccNo: 0000944809-19-000072 Size: 67 KB 网页链接

$Xenetic Biosciences(XBIO)$ 8-K - Current report Filed: 2019-10-08 AccNo: 0001683168-19-003199 Size: 54 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接

$Xenetic Biosciences(XBIO)$ 8-K - Current report Filed: 2019-09-30 AccNo: 0001683168-19-003103 Size: 21 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接

$Xenetic Biosciences(XBIO)$ EFFECT - Notice of Effectiveness Filed: 2019-09-23 AccNo: 9999999995-19-002156 Size: 1 KB 网页链接

$Xenetic Biosciences(XBIO)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2019-09-13 AccNo: 0001683168-19-002928 Size: 180 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21